logo-loader

Physiomics traded in line with expectations

Published: 16:11 30 Jul 2019 AEST

x-ray
Virtual Tumour helps companies work out the optimum combinations of drugs for a specific cancer

Physiomics Plc (LON:PYC) in a short statement confirmed it has traded in line with analysts’ expectations for the year to June 30.

Its Virtual Tumour software predicts the effect of different combinations of drugs on whatever type of cancer a pharmaceutical company might be researching.

Virtual Tumour helps companies work out the optimum combinations of drugs for a specific cancer along with other important elements such as dose sizes and how it should be administered.

It gives a head start when designing development programmes and helps to avoid costly failures especially in clinical trials.

As new cancer drugs can cost up to US$1bn, involve 10 years of work and still fail right at the end of the process, anything developers can do to increase the probability of success is worth something.

So far, Virtual Tumour has been used to model 40-50 types of the disease, but its adaptability means it has the potential to be used across all areas of oncology.

Physiomics in its update said its full-year results would be published in the week starting September 30.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 30 minutes ago